Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Viewpoints - China Shipbuilding Group has signed a new shipbuilding project with China Ocean Shipping Group in Shanghai, involving 87 vessels with a total value of approximately 50 billion RMB, marking the highest single cooperation contract amount for domestic shipbuilding companies in China [2][4]. - The company has enhanced its comprehensive shipbuilding capabilities following the merger with China Shipbuilding Industry Corporation, leading to a robust order backlog and the expectation of continued growth in new orders throughout the year [2][10]. - The lifting of the U.S. 301 investigation measures has alleviated significant pressure on the sector, resulting in a substantial increase in global new orders in November, with a year-on-year growth of 32% and a month-on-month growth of 62% [10]. - The demand for shipping is improving, particularly for oil tankers, which are expected to follow container ship orders, driven by the need for fleet renewal and environmental considerations [10]. Summary by Relevant Sections Company Overview - The new shipbuilding project includes a wide range of vessel types, such as ultra-large container ships, bulk carriers, and oil tankers, with construction primarily handled by subsidiaries of China Shipbuilding [10]. - The company’s order backlog is robust, with orders scheduled until the end of 2028, and some extending to 2029, indicating strong future revenue support [10]. Financial Projections - For the years 2025 and 2026, the company is projected to achieve net profits of 10.315 billion RMB and 18.171 billion RMB, respectively, with corresponding price-to-earnings ratios of 25 times and 14 times [10]. - The total revenue is expected to grow significantly, with projected revenues of 78.584 billion RMB in 2024, increasing to 254.252 billion RMB by 2027 [14]. Market Dynamics - The global shipping industry is experiencing a recovery, with increasing demand for new vessels and rising second-hand ship prices, indicating a potential turning point for new ship prices [10]. - The company is well-positioned to attract global shipbuilding orders due to its technological, capacity, and cost advantages, reinforcing its status as a leading player in the shipbuilding sector [10].

Investment Rating - The industry investment rating is "Positive" and maintained [7] Core Viewpoints - The Wenchang Satellite Super Factory, which can produce 1,000 satellites annually, is set to commence operations, enabling seamless integration of satellite production and launch. This development is expected to significantly shorten the production cycle for individual satellites and facilitate mass production of low Earth orbit (LEO) satellites, thereby accelerating the growth of China's commercial space industry [2][4][9] - The factory's establishment is anticipated to enhance the efficiency of LEO satellite constellation deployment, meeting the growing demand for satellite networks in China. The factory will support the production of 500 kg satellites in bulk, transforming the traditional custom and small-batch satellite manufacturing model [4][9] - The competitive landscape for orbital resources is intensifying, with projections indicating that approximately 57,000 LEO satellites will be deployed by 2029. The factory's operations will contribute to the rapid deployment of satellite constellations, addressing the saturation of communication frequency resources [4][9] Summary by Sections Event Description - The Wenchang Satellite Super Factory is located in Hainan and is designed to produce 1,000 satellites per year. It is the only facility in the country capable of integrating satellite assembly with launch operations, marking it as Asia's largest satellite manufacturing base [4][9] Recent Developments - China's commercial space sector is entering a phase of regular launches, with multiple successful missions completed in December. This trend indicates a shift towards normalized launch operations, driven by technological advancements and increased launch capacity [4][9]

丨证券研究报告丨 [Table_scodeMsg1] 联合研究丨港股公司点评丨小米集团-W（01810.HK） [Table_Title] 汽车业务实现扭亏，Q3 业绩再创新高 报告要点 [Table_Summary] 2025 年前三季度，小米集团实现营收 3403.70 亿元，同比增长 32.5%；经调整净利润 328.17 亿元，同比增长 73.5%。毛利率 22.75%，同比提升 1.69pct；净利率 9.64%，同比提升 2.28pct。 2025Q3 单季度实现营收 1131.21 亿元，同比增长 22.28%；经调整净利润再创新高，达到 113.11 亿元，同比增长 80.92%。毛利率 22.75%，同比提升 1.69pct；净利率 9.64%，同比提升 2.28pct。 分析师及联系人 [Table_Author] 杨洋 高伊楠 陈亮 张永乾 SAC：S0490517070012 SAC：S0490517060001 SAC：S0490517070017 SAC：S0490524030002 SFC：BUW100 SFC：BUW101 SFC：BUW408 请阅读最后评级说明和重要声明 % ...

丨证券研究报告丨 行业研究丨行业周报丨软件与服务 [Table_Title] 2025 年第 49 周计算机行业周报： 朱雀三号发射入轨，关注商业航天产业进展 报告要点 [Table_Summary] 上周计算机板块小幅回撤，整体下跌 1.66%，在长江一级行业中排名第 27 位，两市成交额占 比为 7.12%，商业航天相关标的活跃。上周 DeepSeek-V3.2 和 DeepSeek-V3.2-Speciale 正 式发布；豆包手机助手以技术预览版正式亮相，搭载该功能的努比亚（nubia）M153 工程样机 同步开售；"2025 脑机接口大会"在上海成功举办。本周建议关注产业链各环节的核心供应商， 重点关注卫星应用相关标的。 宗建树 陈耀文 SAC：S0490520030004 SAC：S0490525070002 SFC：BUX668 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 分析师及联系人 [Table_Author] 丨证券研究报告丨 上周关键词：DeepSeek-V3.2、豆包手机助手、脑机接口 2025-12-09 重点推荐：商业航天 朱雀三 ...

Investment Rating - The report maintains a "Positive" investment rating for the communication industry [9]. Core Insights - The communication sector saw a 3.65% increase in the 49th week of 2025, ranking 3rd among major industries, and a 70.43% increase since the beginning of the year, ranking 2nd [2][4]. - AWS launched the Trainium 3 chip, significantly enhancing performance and energy efficiency, while DeepSeek V3.2 made breakthroughs in inference capabilities and cost reduction for long sequences [2][5][6]. - The collaboration between AWS and NVIDIA is expected to accelerate the integration of self-developed chips with the NVIDIA ecosystem, clarifying the ASIC penetration logic [7]. Summary by Sections Market Performance - The communication sector's performance in the 49th week of 2025 was a 3.65% increase, with a year-to-date increase of 70.43% [2][4]. - Top gainers in the sector included Tianfu Communication (+25.8%), Tongyu Communication (+23.9%), and Meige Intelligent (+13.7%), while the largest declines were seen in Online and Offline (-11.8%), Data Port (-10.8%), and Kesi Technology (-8.6%) [4]. Technological Developments - AWS's Trainium 3 chip offers a 4.4x performance increase and a 40% improvement in energy efficiency, reducing training costs for clients by up to 50% [5]. - DeepSeek V3.2, the first open-source model to integrate "deep thinking" and "tool invocation," surpassed GPT-5 in inference benchmarks, significantly lowering costs for long sequence tasks [6]. Investment Recommendations - Recommended companies include China Mobile, China Telecom, and China Unicom in the operator category; Zhongji Xuchuang, Xinyi Sheng, and Tianfu Communication in optical modules; and AI applications such as Boshi Jie, Heertai, and Tuobang Co. [7].

报告要点 固定收益丨深度报告 [Table_Title] 信用债流动性评估进阶指南（上） ——走在债市曲线之前系列报告（十一） %% %% %% %% research.95579.com 1 丨证券研究报告丨 [Table_Summary] 作为信用债流动性评估进阶指南的上篇，本报告聚焦现有信用债流动性评分体系，解析"评分 排名制"与"排名赋分制"两大主流体系的构建逻辑与操作方法，阐述前者主成分分析法的三 步评分流程与后者简单线性回归法的排序赋分规则，明确两种方法的优劣及适配场景；基于截 面和时序视角，分析券种类型、主体评级等多因素对流动性评分的影响规律，总结不同体系下 评分特征与波动情况，为理解信用债流动性评分逻辑提供参考。 分析师及联系人 [Table_Author] 赵增辉 赖逸儒 SAC：S0490524080003 SAC：S0490524120005 SFC：BVN394 SFC：BVZ968 请阅读最后评级说明和重要声明 2 / 26 %% %% %% %% research.95579.com 2 [Table_Title 信用债流动性评估进阶指南（上） 2] ——走在债市曲线之前系列报告（ ...

Economic Outlook - The meeting provided a clear and coherent assessment of the international situation, indicating a readiness to respond, while emphasizing qualitative improvement and reasonable quantitative growth for the domestic economy[1] - The meeting introduced the concept of "quality improvement and efficiency enhancement" as a work guideline, reflecting a focus on sustainable and high-quality development[1] - The emphasis on "domestic demand as the main driver" and "optimizing supply" aims to strengthen the endogenous momentum and reliability of the domestic circulation[1] Risk Management - The focus of risk prevention has shifted from "stabilizing the stock and real estate markets" to "doing practical work," moving from "stabilizing expectations" to "stabilizing reality"[1] - The meeting released numerous positive signals within a limited scope, suggesting a promising start for the "14th Five-Year Plan" and broad growth potential for Chinese assets[1] Policy Adjustments - The policy tone has shifted from "promoting stability through progress" to "quality improvement and efficiency enhancement," indicating a greater emphasis on the quality and sustainability of development[1] - The meeting highlighted the need for "cross-cycle" adjustments in macroeconomic governance, reflecting concerns about enhancing the effectiveness of macroeconomic management[1] Domestic Demand and Supply - The meeting's first mention of "domestic demand as the main driver" and "optimizing supply" signifies a strategic shift towards enhancing domestic demand and improving supply quality[1] - The focus on service consumption as a new engine for expanding domestic demand, particularly in sectors like childcare, education, and healthcare, is expected to drive future growth[1] Market Stability - The meeting did not mention stabilizing the stock and real estate markets, instead emphasizing practical measures to address real economic issues, indicating a shift towards tangible outcomes[1] - The emphasis on "stabilizing employment, enterprises, markets, and expectations" reflects a more grounded approach to economic stability compared to previous years[1]

Investment Rating - The investment rating for the company is "Buy" and is maintained [8] Core Views - The company has maintained strategic stability since establishing its "smart, characteristic, international, and comprehensive" strategy in 2014, emphasizing a stable operational approach in 2024 that aligns with long-term capital preferences in the current market environment [2][12] - The company is expected to continue its stable performance with a focus on capital balance, benefiting from its geographical advantages and the strong growth of investment and financing in Jiangsu province [2][12] - The company's stock price has adjusted significantly since the third quarter, with a projected PB ratio of 0.74x for 2025 and a dividend yield of 5.31%, making it an attractive option among leading city commercial banks [4][6] Summary by Relevant Sections Company Overview - Jiangsu Bank is the largest city commercial bank by market capitalization and is currently undervalued, with a 2025 projected PB ratio of 0.74x and a ROE exceeding 13% [6] - The bank's dividend yield is projected to reach 5.31% in 2025, appealing to long-term capital investors [6] Financial Performance - The bank's loan growth is expected to remain stable, with a significant increase of 17.9% in loans by the end of Q3 2025, and an anticipated total loan increase of approximately 400 billion yuan for the year [12][36] - The bank's net interest margin is projected to stabilize, with a deposit cost of 1.78% in the first half of 2025, allowing for continued high growth in net interest income [12][36] - The asset quality remains stable, with a low proportion of personal operating loans and a projected net generation rate of non-performing loans of 1.10% for the first half of 2025, down 31 basis points from 2024 [12][36] Market Position - The company has seen a significant reduction in active fund holdings, with the proportion of active funds holding Jiangsu Bank shares dropping to 0.12% by the end of Q3, indicating a potential for reallocation of capital towards the bank [6][12] - The bank's capital adequacy ratio is expected to remain above 8.6% by the end of 2025, supporting its asset expansion [12][36]

[Table_scodeMsg1] 公司研究丨深度报告丨海光信息（688041.SH） [Table_Title] 海光信息深度报告：双轮驱动，国产算力新生态 research.95579.com 1 丨证券研究报告丨 报告要点 [Table_Summary] 海光信息是我国国产高端 CPU 和 DCU 双领军企业，其高端通用 CPU 业务随着信创深入推进， 凭借生态优势、性能优势和安全优势等综合优势最大受益持续高速增长。DCU 业务在 AI 时代 国产算力总量和份额双升趋势下凭借产品持续迭代和"类 CUDA"环境兼容以及和中科曙光协 同有望迎来爆发。拟吸收合并中科曙光，将其具备从核心 AI 芯片到智算集群单点到全栈的产品 和综合能力，发布业界领先超节点产品，有望通过" AI 计算开放架构"打造国产算力新生态， 成长为我国 AI 时代算力综合平台。 分析师及联系人 [Table_Author] 宗建树 余庚宗 SAC：S0490520030004 SAC：S0490516030002 SFC：BUX668 %% %% %% %% 请阅读最后评级说明和重要声明 2 / 40 %% %% %% %% resear ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [12][14]. Core Insights - The company, Genting Biopharma, focuses on innovative drug and vaccine research, manufacturing, and commercialization, establishing a dual-driven growth model through license-in products and self-developed high-barrier pipelines [3][8]. - Key products include Nefukang (Budesonide) for IgA nephropathy, EVER001 for primary membranous nephropathy, and Aicuo Mod (Etrolizumab) for moderate to severe ulcerative colitis, all showing significant clinical evidence and market potential [9][10][11]. - The company has seen substantial revenue growth, with projected revenues of 1.791 billion, 3.169 billion, and 4.822 billion RMB for 2025-2027, respectively, and a turnaround in profitability expected by 2025 [12][30]. Summary by Sections Company Overview - Genting Biopharma was founded in July 2017 and has developed a diverse product pipeline covering oncology, nephrology, and infectious diseases [18]. - The company has shifted focus towards nephrology and autoimmune diseases, divesting from oncology to enhance resource allocation [18]. Product Pipeline - The product pipeline includes Nefukang, which is the first approved drug for IgA nephropathy globally, and EVER001, a reversible BTK inhibitor targeting primary membranous nephropathy [9][10]. - Aicuo Mod has shown rapid efficacy in inducing clinical remission in ulcerative colitis patients, with a significant mucosal healing rate [11]. Financial Performance - The company achieved a revenue of 707 million RMB in 2024, a 461% increase year-on-year, and expects continued growth with a revenue of 446 million RMB in the first half of 2025 [28][30]. - The net profit is projected to improve from a loss of 376 million RMB in 2025 to a profit of 868 million RMB by 2027, indicating a strong recovery trajectory [12][30]. Market Potential - The chronic kidney disease (CKD) patient population is substantial, with approximately 1.25 billion patients in China, representing a significant market opportunity for the company's nephrology products [32]. - The company’s products are positioned to address unmet medical needs in the nephrology and autoimmune disease sectors, with a focus on innovative treatment approaches [3][8].